So far, immune cells that have been engineered to kill cancers, known as CAR T-cells, haven’t worked well against solid ...

Among 16 patients with this difficult-to-treat tumor "with few treatment options," the confirmed overall response rate (ORR) ...

The ability of immune cells—particularly CD8+ T cells—to launch a rapid burst of proliferation inside tumors is key to the ...

Some 68% of patients with autoimmune disease had "major" side effects from CAR-T therapy for myeloma, lymphoma, or leukemia, ...

Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main ...

In 2015, Bluestone led a small clinical trial to isolate and grow Tregs from diabetes patients and then reinfuse the cells ...

The ability of immune cells-particularly CD8+ T cells-to launch a rapid burst of proliferation inside tumors is key to the ...

The oncology pipeline is marked by heterogeneity and complexity (1). Moving forward, pharmaceutical scientists must navigate the intersection of advanced biology, next-generation delivery platforms, ...

A pan-immunotherapy biomarker predicts and reactivates CD8⁺ T cell expansion, offering new insight into treatment response.

Liberate Bio’s CAR-M cell therapy almost completely depleted B-cells in a nonhuman primate study, the company said.

Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...